title: What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT?
authors.forename: A
authors.initials: A
authors.lastname: Candoni
authors.forename: E
authors.initials: E
authors.lastname: Simeone
authors.forename: M
authors.initials: M
authors.lastname: Tiribelli
authors.forename: C
authors.initials: C
authors.lastname: Pipan
authors.forename: R
authors.initials: R
authors.lastname: Fanin
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D012449:Safety; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir